

Date: 13<sup>th</sup> May, 2026

To,  
The Manager - Listing Compliance Department,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra East, Mumbai – 400 051,  
Maharashtra, India

**NSE Symbol - NEOCHEM**

Dear Sir/Madam,

**Sub: Monitoring Agency Report for the quarter ended March 31, 2026**

**Ref: Neochem Bio Solutions Limited (SYMBOL: NEOCHEM, ISIN: INE21UM01018),  
Quarter ended 31<sup>st</sup> March, 2026**

Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, read along with SEBI (Issue of Capital and Disclosure Requirements) Regulations, please find enclosed herewith the First Monitoring Agency Report dated May 11, 2026, for the quarter ended on March 31, 2026 in respect of utilization of proceeds of the Initial Public Offer (“IPO”) of the Company.

This submission will be disseminated on the Company’s website at [www.neochem.in](http://www.neochem.in)

We request you to kindly take the above information on record.

Thanking you.

**For NEOCHEM BIO SOLUTIONS LIMITED**

***(Formerly known as Neochem Bio Solutions Private Limited and Neochem Technologies Private Limited)***

**SWAPNIL RAMESHBHAI MAKATI**

**Managing Director**

**DIN: 00188382**

**Second and Final  
Monitoring Agency Report for  
Neochem Bio Solutions Limited  
for the quarter ended  
March 31, 2026**

**No. BWR/2026-27/IPM/NBSL/02**  
May 11,2026

To,  
**Mr. Pradip Ramniklal Solanki**  
**Chief Financial Officer**  
**Neochem Bio Solutions Limited**  
**303, W1, Opp. Vikram Nagar Colony,**  
**Off. Iscon-Ambli Road,**  
**Ahmedabad - 380058,**  
**Daskroi, Gujarat, India**

Dear Sir,

**Second and Final Monitoring Agency Report for the quarter ended March 31, 2026 - in relation to the Fresh Issue of Equity Shares of Neochem Bio Solutions Limited (“the Company”)**

Pursuant to client 's request and Monitoring Agency Engagement Letter dated October 30,2025, Brickwork Ratings (BWR) has prepared the Second and Final Monitoring Agency Report, as per Schedule XI of the SEBI ICDR Regulations towards utilisation of proceeds of funds raised, for the quarter ended March 31, 2026.

The funds raised by the Company were through Fresh Issue of Equity Shares aggregating to Rs.44.97 Crore of the Company.

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended March 31, 2026, as per Monitoring Agency Agreement dated November 15,2025.

Request you to kindly take the same on records.

Thanking you,

Yours Faithfully,

**NIRAJ  
KUMAR  
RATHI**

Digitally signed by  
**NIRAJ KUMAR RATHI**  
Date: 2026.05.11  
18:33:14 +05'30'

**Mr. Niraj Kumar Rathi**  
Senior Director, Ratings - Brickwork Ratings

**Report of the Monitoring Agency (MA)****Name of the issuer:** Neochem Bio Solutions Limited**For quarter ended:** March 31, 2026**Name of the Monitoring Agency:** Brickwork Ratings India Private Limited

(a) Deviation from the objects: No

(b) Range of Deviation: Not Applicable

**Declaration:**

*We declare that this report is based on the format prescribed by the SEBI (ICDR) Regulations, 2018, we further declare that this report provides a true and fair view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable.*

*We declare that we do not have any direct/indirect interest in or relationship with the issuer/promoters/directors/management and confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer.*

*The MA does not perform an audit and undertakes no independent verification of any information/certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.*

*The MA or its affiliates may have a credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.*

*We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors after the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.*

**NIRAJ KUMAR RATHI** Digitally signed by  
NIRAJ KUMAR RATHI  
Date: 2026.05.11  
18:33:52 +05'30'

**Signature:****Name of the Authorized Signatory: Mr. Niraj Kumar Rathi****Designation of Authorized Person/Signing Authority: Senior Director, Ratings - Brickwork Ratings**

**1) Issuer Details:**

Name of the issuer:	Neochem Bio Solutions Limited
Names of the promoters:	Mr. Swapnil Rameshbhai Makati and Mrs. Hemangini Swapnil Dathia
Industry / sector to which it belongs:	Manufacturing and trading of chemicals

**2) Issue Details:**

For Anchor Investors:	December 01, 2025, to December 01, 2025
For Others:	December 02, 2025, to December 04, 2025
Type of issue (public/ rights):	Fresh Issue of Equity shares
Type of specified securities:	Equity Shares
IPO Grading, if any:	Not Applicable
Issue size (in ₹ Crore):	44.97

Particulars	Total Number of Securities	Price (₹)	Value as per Offer Document (₹ Crore)	Amount Received (₹ Crore)
<b>Equity Shares-Fresh Issue</b>	45,88,800	98	44.97	44.97
<b>Total</b>	<b>45,88,800</b>	<b>98</b>	<b>44.97</b>	<b>44.97</b>

**3) Details of the arrangement made to ensure the monitoring of issue proceeds:**

Particulars	Reply	Source of information / certifications considered by Monitoring Agency for preparation of report	Comments of Monitoring Agency	Comments of Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	Bank Statements, Invoices, Company's Letter, CA Certificate.	Nil	Nil
Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document?	Not Applicable	Nil	Nil	Nil
Whether the means of finance for the disclosed objects of the issue has changed?	No	Nil	Nil	Nil
Is there any major deviation observed over the earlier monitoring agency reports?	Not Applicable	Nil	NIL	Nil
Whether all Government/statutory approvals related to the object(s) have been obtained?	Yes	Company's letter	Nil	Nil
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	Not Applicable	Nil	Nil	Nil
Are there any favourable events improving the viability of these object(s)?	No	Company's letter	Nil	Nil
Are there any unfavourable events affecting the viability of the object(s)?	No	Company's letter	Nil	Nil
Is there any other relevant information that may materially affect the decision making of the investors?	No	Not Applicable	Nil	Nil

*Note: The above details are verified by Patel Mehta & Associates Chartered Accountants FRN No. 107773W vide its CA Certificate and company statement dated May 11, 2026.*

*#Where material deviation may be defined to mean:*

- (a) Deviation in the objects or purposes for which the funds have been raised
- (b) Deviation in the amount of funds utilised by more than 10% of the amount projected in the offer documents.

**4) Details of object(s) to be monitored:**

**i. Cost of object(s):**

Sr. No.	Item Head	Source of information / certifications considered by Monitoring Agency for preparation of report	Original Cost (as per the Offer Document) (₹ Crore)	Revised Cost (₹ Crore)	Comments of the Monitoring Agency	Comments of the Board of Directors		
						Reason of cost revision	Proposed financing option	Particulars of firm arrangements made
1.	Funding the long-term working capital requirements of the company	Bank Statements, Company Letter, CA Certificate	23.90	No	Nil	Nil	Nil	Nil
2	Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by company	Bank Statements, Company Letter, CA Certificate	10.00	No	Nil	Nil	Nil	Nil
3.	General corporate purposes	Bank Statements, Company Letter, CA Certificate	6.44	No	Nil	Nil	Nil	Nil
4.	Issue expenses	Bank Statements, Company Letter, CA Certificate	4.63	No	Nil	Nil	Nil	Nil
5.	Any other purpose approved by board	NA	Nil	No	Nil	Nil	Nil	Nil

*Note: The above details are verified by Patel Mehta & Associates Chartered Accountants FRN No. 107773W vide its CA Certificate and company statement dated May 11, 2026.*

**ii. Progress in the object(s):**

Sr. No.	Item Head	Source of information/certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document in ₹ Crore (A)	Amount utilized in ₹ Crore (B)			Total Unutilised amount in ₹ Crore as on 31 <sup>st</sup> March 2026 (C) A-B	Comments of the Monitoring Agency
				As at beginning of the quarter in ₹ Crore	During the quarter in ₹ Crore	At the end of the quarter in ₹ Crore		
1.	Funding the long-term working capital requirements of the company	Bank Statements, Company Letter, CA Certificate	23.90	20.86	3.04	23.90	0.00	Nil
2	Repayment/prepayment, in full or part, of all or certain outstanding borrowings availed by company	Bank Statements, Company Letter, CA Certificate	10.00	0.00	10.00	10.00	0.00	Nil
3.	General corporate purposes	Bank Statements, Company Letter, CA Certificate	6.44	1.04	5.40	6.44	0.00	Nil
4.	Issue expenses	Bank Statements, Company Letter, CA Certificate	4.63	4.44	0.19	4.63	0.00	Nil
5.	Any other purpose approved by board	NA	Nil	Nil	Nil	Nil	Nil	Nil

*Note: The above details are verified by Patel Mehta & Associates Chartered Accountants FRN No. 107773W vide its CA Certificate and company statement dated May 11, 2026.*

**iii. Deployment of unutilised issue proceeds:**

Sr. No.	Type of instrument and name of entity invested in	Amount Invested (₹ Crore)	Maturity date	Earning (₹ Crore)	Return on Investment (%)	Market Value as at the end of the quarter
<b>No unutilized amount available for deployment during the quarter ended March 31, 2026</b>						

Note: The above details are verified by Patel Mehta & Associates Chartered Accountants FRN No. 107773W vide its CA Certificate and company statement dated May 11, 2026.

**iv. Delay in Implementation of Objects:**

Object(s) Name	Completion Date		Delay	Comments of Board of Directors	
	As per Offer Document	Actual	No. of Days/ Months	Reason of Delay	Proposed course of Action
<b>Funding the long-term working capital requirements of the company</b>	Up to Financial Year 2026-27	Completed	-	-	-
<b>Repayment/ prepayment, in full or part, of all or certain outstanding borrowings availed by company</b>	Up to Financial Year 2025-26	Completed	-	-	-
<b>General corporate purposes</b>	Up to Financial Year 2025-26	Completed	-	-	-
<b>Issue expenses</b>	-	-	-	-	-
<b>Any other purpose approved by board</b>	-	-	-	-	-

The above details are verified by company statement dated May 11, 2026.

**5) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:**

Item head	Amount in Rs. Crore (As on March 31,2026)	Remarks
<b>General corporate purpose*</b>	<b>6.44</b>	<b>Nil</b>

Note: The above details are verified by Patel Mehta & Associates Chartered Accountants FRN No. 107773W vide its CA Certificate and company statement dated May 11, 2026.

As per page no. 118 of prospectus dated December 04, 2025, General Corporate expenses include but not restricted to

a) applying the balance amount towards part or full repayment/prepayment of outstanding borrowings: b) meeting additional working capital requirements: c) capital expenditure: d) funding growth opportunities including strategic initiatives e) meeting expenses incurred in the ordinary course of business including salaries and wages, administration expenses, insurance related expenses; f) meeting of exigencies which Company may face in course of business and any other purpose as may be approved by the Board or a duly appointed committee from time to time, subject to compliance with applicable law, including the necessary provisions of the Companies Act.

## Disclaimer

- a) This Report is prepared by **Brickwork Ratings India Private Limited** (hereinafter referred to as “**BWR**” or “**Monitoring Agency**” or “**MA**”). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal with any security of the Issuer in any manner whatsoever.
- b) This Report must be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.
- c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.
- d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013.
- e) While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.
- f) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.
- g) **BWR** is an independent Monitoring Agency and may determine, apply and amend its approach, processes and procedures in its sole discretion from time to time provided the same are in line with the SEBI ICDR Regulations.